<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phkinetica</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакокинетика и Фармакодинамика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacokinetics and Pharmacodynamics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7836</issn><issn pub-type="epub">2686-8830</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">phkinetica-41</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРОТЕОМНЫЙ АНАЛИЗ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PROTEOMIC ANALYSIS</subject></subj-group></article-categories><title-group><article-title>Протеомный анализ эффектов тиоктовой кислоты в составе меглюмина тиоктата</article-title><trans-title-group xml:lang="en"><trans-title>Proteomic analysis of the effects of thioctic acid within meglumine thioctate</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Торшин</surname><given-names>И. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Torshin</surname><given-names>I. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Громова</surname><given-names>Ольга Алексеевна</given-names></name><name name-style="western" xml:lang="en"><surname>Gromova</surname><given-names>O. A.</given-names></name></name-alternatives><email xlink:type="simple">unesco.gromova@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Койфман</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Koifman</surname><given-names>O. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Майорова</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Maiorova</surname><given-names>L. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ФИЦ ИУ РАН Институт современных информационных технологий в медицине; ГБАОУ ВО «Ивановский государственный химико-технологический университет»</institution><country>Russian Federation</country></aff><aff xml:lang="ru" id="aff-2"><institution>ФИЦ ИУ РАН Институт современных информационных технологий в медицине; Федеральное государственное бюджетное образовательное учреждение высшего образования «Ивановская государственная медицинская академия» Министерства здравоохранения Российской Федерации</institution><country>Russian Federation</country></aff><aff xml:lang="ru" id="aff-3"><institution>ГБАОУ ВО «Ивановский государственный химико-технологический университет»</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>06</day><month>11</month><year>2017</year></pub-date><volume>0</volume><issue>4</issue><fpage>24</fpage><lpage>30</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Торшин И.Ю., Громова О.А., Койфман О.И., Майорова Л.А., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Торшин И.Ю., Громова О.А., Койфман О.И., Майорова Л.А.</copyright-holder><copyright-holder xml:lang="en">Torshin I.I., Gromova O.A., Koifman O.I., Maiorova L.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacokinetica.ru/jour/article/view/41">https://www.pharmacokinetica.ru/jour/article/view/41</self-uri><abstract><p>Протеомный анализ указал на 6 таргетных белков тиоктовой кислоты (ТК) и 11 белков метаболизма ТК. Все установленные белки являются митохондриальными белками. В таргетных белках (P-белок, H-белок, липоамид ацилтрансфераза, дигидролипо-иллин ацетилтрансфераза, Х-белок пируватдегидрогеназы, дигидролипоиллизин сукцинилтрансфераза) ТК является кофактором, ковалентно связанным со специфическими остатками лизина и необходима для переработки глицина и других аминокислот, поддержания активности цикла Кребса. Недостаточная активность этих таргетных белков (вследствие генетических дефектов или глубокого дефицита ТК) приводит к митохондриальной недостаточности, гиперглицинемии, билиарному циррозу, синдрому «мочи кленового сиропа» и другим нарушениям метаболизма. Недостаточная активность 11 белков метаболизма ТК ассоциирована со множественными нарушениями функции митохондрий, лактоацидозом и анемией. Таким образом, ТК принципиально важна для поддержки функции митохондрий и энергетического метаболизма клетки.</p></abstract><trans-abstract xml:lang="en"><p>Proteomic analysis indicated 6 target proteins of thioctic acid (TA) and 11 proteins of TA metabolism, all of which are mitochondrial proteins. In the structure of the target proteins (namely, P-protein, H-protein, lipoamide acyltransferase, dihydrolipoyline acetyltransferase, X-protein pyruvate dehydrogenase, dihydrolyloylizine succinyltransferase), TA is a cofactor which is covalently bound to specific lysine residues and which is required for processing glycine and other amino acids, thus maintaining the activity of the Krebs cycle. Insufficient activity of these target proteins (due to either genetic defects or nutritional TA deficiency) leads to mitochondrial insufficiency, hyperglycinemia, biliary cirrhosis, "maple syrup urine" syndrome and other metabolic disorders. Insufficient activity of the 11 proteins of TA metabolism is associated with multiple disorders of mitochondrial function, lactic acidosis and anemia. Thus, TA is fundamentally important for supporting the function of mitochondria and of the cellular energy metabolism.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>тиоктовая кислота</kwd><kwd>меглюмина тиоктат</kwd><kwd>протеомика</kwd><kwd>митохондриальная недостаточность</kwd><kwd>биоинформатика</kwd><kwd>Тиогамма</kwd><kwd>thioctic acid</kwd><kwd>meglumine tioctate</kwd><kwd>proteomics</kwd><kwd>mitochondrial insufficiency</kwd><kwd>bioinformatics</kwd><kwd>Thiogamma</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Клинико-фармакологическая статья «Тиоктовая кислота». Обращение лекарственных средств. ФГУ «Научный центр экспертизы средств медицинского применения» Росздравнадзора РФ (27.03.2008).</mixed-citation><mixed-citation xml:lang="en">Клинико-фармакологическая статья «Тиоктовая кислота». Обращение лекарственных средств. ФГУ «Научный центр экспертизы средств медицинского применения» Росздравнадзора РФ (27.03.2008).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma M., Gupta Y.K. Effect of alpha lipoic acid on intracerebroventricular treptozotocin model of cognitive impairment in rats. Eur. Neuropsychopharmacol. 2003; 4 (13): 241-247.</mixed-citation><mixed-citation xml:lang="en">Sharma M., Gupta Y.K. Effect of alpha lipoic acid on intracerebroventricular treptozotocin model of cognitive impairment in rats. Eur. Neuropsychopharmacol. 2003; 4 (13): 241-247.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ziegler D., Hanefeld M., Ruhnau K.J. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic 4. Malik R.A. Current and future strategies for the management of diabetic neuropathy. Treat Endocrinol. 2003; 2 (6): 389-400.</mixed-citation><mixed-citation xml:lang="en">Ziegler D., Hanefeld M., Ruhnau K.J. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic 4. Malik R.A. Current and future strategies for the management of diabetic neuropathy. Treat Endocrinol. 2003; 2 (6): 389-400.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Poon H.F., Farr S.A., Thongboonkerd V. et al. Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neurodegenerative disorders. Neurochem. Int. 2005; 2 (46): 159-168.</mixed-citation><mixed-citation xml:lang="en">Poon H.F., Farr S.A., Thongboonkerd V. et al. Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neurodegenerative disorders. Neurochem. Int. 2005; 2 (46): 159-168.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Cho J.Y., Um H.S., Kang E.B., Cho I.H., Kim C.H., Cho J.S., Hwang D.Y. The combination of exercise training and alpha-lipoic acid treatment has therapeutic effects on the pathogenic phenotypes of Alzheimer's disease in NSE/APPsw-transgenic mice. Int J Mol Med. 2010; 25 (3): 337-346.</mixed-citation><mixed-citation xml:lang="en">Cho J.Y., Um H.S., Kang E.B., Cho I.H., Kim C.H., Cho J.S., Hwang D.Y. The combination of exercise training and alpha-lipoic acid treatment has therapeutic effects on the pathogenic phenotypes of Alzheimer's disease in NSE/APPsw-transgenic mice. Int J Mol Med. 2010; 25 (3): 337-346.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Torshin I.Yu. Sensing the change from molecular genetics to personalized medicine. Nova Biomedical Books, NY, USA, 2009, In “Bioinformatics in the Post-Genomic Era” series, ISBN 1-60692-217-0.</mixed-citation><mixed-citation xml:lang="en">Torshin I.Yu. Sensing the change from molecular genetics to personalized medicine. Nova Biomedical Books, NY, USA, 2009, In “Bioinformatics in the Post-Genomic Era” series, ISBN 1-60692-217-0.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Биохимия: учебник для вузов (ред. Е.С. Северин), М.: 5-е изд., 2009.</mixed-citation><mixed-citation xml:lang="en">Биохимия: учебник для вузов (ред. Е.С. Северин), М.: 5-е изд., 2009.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Teichert J., Hermann R., Ruus P., Preiss R. Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers. J Clin Pharmacol., 2003, 43 (11): 1257-1267. doi: 10.1177/0091270003258654.</mixed-citation><mixed-citation xml:lang="en">Teichert J., Hermann R., Ruus P., Preiss R. Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers. J Clin Pharmacol., 2003, 43 (11): 1257-1267. doi: 10.1177/0091270003258654.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
